💊
Zynteglo
betibeglogene autotemcel
beta-Talassemia
🚫 Ritirato
Terapia avanzata
✅
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Zynteglo is indicated for the treatment of patients 12 years and older with transfusion-dependent β thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.
⚠️ Sicurezza del paziente
No
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo